Categories
Categories
- Press release (9)
- Publication (2)
- Scientific publication (4)
- Status update (2)
Latest news
PureIMS appoints Jaap Wieling, PhD, as new CEO
Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic
Levodopa Cyclops™ in Dutch magazine ‘Tijdschrift voor Neurologie en Neurochirurgie (TNN)’
Inhaled levodopa for the rescue treatment of OFF episodes in Parkinson’s disease OFF episodes are an unmet medical need with a great impact on the
PureIMS participating in Biotech Showcase™ 2022
PureIMS aims to find a partner for its lead program Levodopa Cyclops™ Roden — December 22, 2021 — PureIMS today announced that it is participating
Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline
Roden — July 7, 2021 — Mycobacterium abscessus is a nontuberculous mycobacterium (NTM) that primarily causes severe pulmonary infections. The pathogen is also known as
PureIMS to present at Biotech Showcase™ Digital 2021
PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization Roden — December 16, 2020 — PureIMS today
Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility
I. Sibum, P. Hagedoorn, C.O. Botterman, H.W. Frijlink and F. Grasmeijer In recent years there has been increasing interest in the pulmonary delivery of high
PureIMS in Harro Magazine!
We are honoured that Harro Hӧfliger published an article on PureIMS in their Harro Magazine! Full article here
PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis
Delivery via inhaler could dramatically expand Amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. Roden — July 1st, 2020 — PureIMS,
Hydroxychloroquine Cyclops in Dutch pharmacy magazine ‘Pharmaceutisch Weekblad’
In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working
PureIMS joins the battle against Coronavirus (COVID-19)
In a joint effort with UMCG, University of Groningen and several international partners, PureIMS is actively battling the COVID-19 pandemic by repurposing hydroxychloroquine for pulmonary
PureIMS present at DDL
PureIMS will be present at the Drug Delivery to the Lungs Conference 2019 in Edinburgh. Please visit our stand (507)!
PIMS-E website launched!
PIMS-Epinephrine (PIMS-E) has just launched its new website! PIMS-E uses the Cyclops™ dry powder inhaler to develop a better alternative to epinephrine auto-injectors for the
Cyclops as example of the TopDutch pioneering and collaborating mentality
The Cyclops™ pre-loaded disposable dry powder inhaler is a product of TopDutch’s life science & health industry and mentioned as an example of the TopDutch
Carduso Capital invests in PIMS-E
Carduso Capital invests in PIMS-E, a Spin-off company of the University of Groningen that aims to develop an epinephrine dry powder inhaler as alternative to
Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer International Journal of Pharmaceutics, 2019, 11 (5) (DOI: 10.3390/pharmaceutics11050233)
Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease
M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink Pharmacokinetics and tolerability
Learning from Parkinson’s patients: Usability of the Cyclops dry powder inhaler
M. Luinstra, V. Isufi, L. de Jong, A.W.F. Rutgers, P. Hagedoorn, J. Puttenstein, T. van Laar, H.W. Frijlink International Journal of Pharmaceutics, 2019, 567, p.